Lowest-Rated StocksLowest-RatedNASDAQ:CBAY CymaBay Therapeutics (CBAY) Stock Price, News & Analysis → The AI Defense Stock Set to Soar (From Behind the Markets) (Ad) Free CBAY Stock Alerts $32.48 +0.01 (+0.03%) (As of 03/22/2024) Add Compare Share Share Today's Range$32.48▼$32.5050-Day Range$22.46▼$32.4852-Week Range$7.26▼$32.50Volume8.36 million shsAverage Volume4.11 million shsMarket Capitalization$3.73 billionP/E RatioN/ADividend YieldN/APrice Target$28.65 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get CymaBay Therapeutics alerts: Email Address CymaBay Therapeutics MarketRank™ Stock AnalysisAnalyst RatingHold2.08 Rating ScoreUpside/Downside11.8% Downside$28.65 Price TargetShort InterestHealthy5.10% of Shares Sold ShortDividend StrengthN/ASustainability-0.88Upright™ Environmental ScoreNews Sentiment0.67Based on 8 Articles This WeekInsider TradingSelling Shares$1.12 M Sold Last QuarterProj. Earnings GrowthGrowingFrom ($1.38) to ($1.37) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.74 out of 5 starsMedical Sector266th out of 939 stocksPharmaceutical Preparations Industry121st out of 433 stocks 2.0 Analyst's Opinion Consensus RatingCymaBay Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.08, and is based on 1 buy rating, 11 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $28.65, CymaBay Therapeutics has a forecasted downside of 11.8% from its current price of $32.48.Amount of Analyst CoverageCymaBay Therapeutics has been the subject of 11 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 4.0 Short Interest Percentage of Shares Shorted5.10% of the outstanding shares of CymaBay Therapeutics have been sold short.Short Interest Ratio / Days to CoverCymaBay Therapeutics has a short interest ratio ("days to cover") of 1.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in CymaBay Therapeutics has recently decreased by 30.11%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldCymaBay Therapeutics does not currently pay a dividend.Dividend GrowthCymaBay Therapeutics does not have a long track record of dividend growth. Previous Next 4.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreCymaBay Therapeutics has received a 74.24% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Clinical research services for physical health" and "Preclinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for CymaBay Therapeutics is -0.88. Previous Next 2.0 News and Social Media Coverage News SentimentCymaBay Therapeutics has a news sentiment score of 0.67. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 8 news articles for CymaBay Therapeutics this week, compared to 4 articles on an average week.Search InterestOnly 9 people have searched for CBAY on MarketBeat in the last 30 days. This is a decrease of -10% compared to the previous 30 days.MarketBeat FollowsOnly 15 people have added CymaBay Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -29% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, CymaBay Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,124,279.00 in company stock.Percentage Held by InsidersOnly 7.00% of the stock of CymaBay Therapeutics is held by insiders.Percentage Held by Institutions95.03% of the stock of CymaBay Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for CymaBay Therapeutics are expected to grow in the coming year, from ($1.38) to ($1.37) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of CymaBay Therapeutics is -33.48, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of CymaBay Therapeutics is -33.48, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCymaBay Therapeutics has a P/B Ratio of 12.59. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Behind the MarketsThe AI Defense Stock Set to SoarTo protect our interests, The Pentagon has partnered with this small AI defense contractor - creating some of the most powerful AI defenses ever made.Here's how you can invest >>> About CymaBay Therapeutics Stock (NASDAQ:CBAY)CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta for the treatments of primary biliary cholangitis (PBC). The company also develops MBX-2982, a G protein-coupled receptor 119 (GPR119) agonist, in subjects with type 1 diabetes. It has a license agreement with ABW Cyclops SPV LP to support development of seladelpar for the treatment of PBC. The company was formerly known as Metabolex, Inc. CymaBay Therapeutics, Inc. was incorporated in 1988 and is headquartered in Fremont, California.Read More CBAY Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CBAY Stock News HeadlinesMarch 25, 2024 | americanbankingnews.comCymaBay Therapeutics (NASDAQ:CBAY) Coverage Initiated by Analysts at StockNews.comMarch 22, 2024 | za.investing.comGilead reduces 2024 earnings guidance after completing CymaBay takeoverMarch 28, 2024 | Behind the Markets (Ad)The AI Defense Stock Set to SoarTo protect our interests, The Pentagon has partnered with this small AI defense contractor - creating some of the most powerful AI defenses ever made.March 22, 2024 | markets.businessinsider.comGilead Sciences Completes Acquisition Of CymaBay TherapeuticsMarch 22, 2024 | businesswire.comGilead Sciences Announces Completion of Acquisition of CymaBayMarch 16, 2024 | finance.yahoo.comCBAY Jul 2024 34.000 callMarch 16, 2024 | finance.yahoo.comCBAY Apr 2024 31.000 putMarch 16, 2024 | finance.yahoo.comCBAY Oct 2024 33.000 callMarch 28, 2024 | Behind the Markets (Ad)The AI Defense Stock Set to SoarTo protect our interests, The Pentagon has partnered with this small AI defense contractor - creating some of the most powerful AI defenses ever made.March 16, 2024 | finance.yahoo.comCBAY Oct 2024 29.000 putMarch 11, 2024 | finance.yahoo.comInvesting in CymaBay Therapeutics (NASDAQ:CBAY) three years ago would have delivered you a 540% gainMarch 4, 2024 | globenewswire.comCymaBay Announces European Medicines Agency Accepts for Review the Marketing Authorization Application for Seladelpar for the Treatment of Primary Biliary CholangitisFebruary 29, 2024 | markets.businessinsider.comMaintaining Hold on CymaBay Amid Gilead Acquisition Deal ClosureFebruary 29, 2024 | markets.businessinsider.comSHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of CymaBay Therapeutics, Inc. (CBAY)February 28, 2024 | marketwatch.comCymaBay Therapeutics 4Q Loss/Shr 35c >CBAYFebruary 28, 2024 | globenewswire.comCymaBay Reports Fourth Quarter and Year Ended December 31, 2023 Financial Results and Provides Corporate UpdateFebruary 24, 2024 | msn.comCymaBay Therapeutics (CBAY) Price Target Increased by 12.84% to 31.37February 21, 2024 | finance.yahoo.comThe New England Journal of Medicine Publishes Positive Phase 3 RESPONSE Data of CymaBay's Seladelpar in Primary Biliary CholangitisFebruary 21, 2024 | prnewswire.comThe New England Journal of Medicine Publishes Positive Phase 3 RESPONSE Data of CymaBay's Seladelpar in Primary Biliary CholangitisFebruary 20, 2024 | msn.comLeerink Partners Downgrades CymaBay Therapeutics (CBAY)February 20, 2024 | globenewswire.comCymaBay Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)February 16, 2024 | businesswire.comCYMABAY THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of CymaBay Therapeutics, Inc. - CBAYFebruary 15, 2024 | finance.yahoo.comCBAY Jan 2026 37.000 callFebruary 14, 2024 | finance.yahoo.comCBAY Feb 2024 33.000 callFebruary 14, 2024 | finance.yahoo.comCBAY Jan 2025 8.000 putFebruary 13, 2024 | seekingalpha.comCymaBay's Seladelpar Is A Solid, But Pricey, Addition To Gilead's Liver FranchiseFebruary 12, 2024 | msn.comGilead Eyes Expanded Liver Treatment Portfolio With $4.3 Billion Buyout of CymaBay TherapeuticsSee More Headlines Receive CBAY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for CymaBay Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/28/2024Today3/28/2024Next Earnings (Estimated)5/20/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:CBAY CUSIPN/A CIK1042074 Webwww.cymabay.com Phone(510) 293-8800Fax510-293-9090Employees101Year FoundedN/APrice Target and Rating Average Stock Price Target$28.65 High Stock Price Target$32.50 Low Stock Price Target$15.00 Potential Upside/Downside-11.8%Consensus RatingHold Rating Score (0-4)2.08 Research Coverage12 Analysts Profitability EPS (Most Recent Fiscal Year)($0.97) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-105,370,000.00 Net MarginsN/A Pretax Margin-339.11% Return on Equity-50.72% Return on Assets-31.04% Debt Debt-to-Equity RatioN/A Current Ratio10.96 Quick Ratio10.96 Sales & Book Value Annual Sales$31.07 million Price / Sales119.92 Cash FlowN/A Price / Cash FlowN/A Book Value$2.58 per share Price / Book12.59Miscellaneous Outstanding Shares114,724,000Free Float106,693,000Market Cap$3.73 billion OptionableOptionable Beta0.32 20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free Report Key ExecutivesMr. Sujal A. Shah (Age 51)President, CEO & Director Comp: $1.04MDr. Charles A. McWherter Ph.D. (Age 69)President of Research & Development and Chief Scientific Officer Comp: $700.65kMr. Paul T. Quinlan (Age 61)General Counsel, Chief Compliance Officer & Corporate Secretary Comp: $629.72kMr. Harish Shantharam C.F.A. (Age 42)CFO, Principal Accounting & Financial Officer Mr. Ken BoehmSenior Vice President of Human ResourcesMr. Patrick J. O'Mara (Age 63)Senior Vice President of Business Development Dr. Robert L. Martin (Age 62)Senior Vice President of Manufacturing & Nonclinical Development Ms. Klara A. Dickinson-Eason (Age 56)Chief Regulatory & Quality Assurance Officer Comp: $441.84kMs. Becki Filice (Age 63)Senior Vice President of Portfolio & Product Leadership Mr. Ben KozubHead of CommercialMore ExecutivesKey CompetitorsUltragenyx PharmaceuticalNASDAQ:RAREAxsome TherapeuticsNASDAQ:AXSMBausch Health CompaniesNYSE:BHCPrestige Consumer HealthcareNYSE:PBHArrowhead PharmaceuticalsNASDAQ:ARWRView All CompetitorsInsiders & InstitutionsPNC Financial Services Group Inc.Bought 7,756 shares on 3/22/2024Ownership: 0.007%Vanguard Group Inc.Bought 558,562 shares on 3/11/2024Ownership: 5.497%Wellington Management Group LLPBought 202,782 shares on 3/5/2024Ownership: 0.177%Tucker Asset Management LLCBought 3,749 shares on 3/4/2024Ownership: 0.003%Goldman Sachs Group Inc.Bought 69,974 shares on 3/1/2024Ownership: 0.556%View All Insider TransactionsView All Institutional Transactions CBAY Stock Analysis - Frequently Asked Questions Should I buy or sell CymaBay Therapeutics stock right now? 12 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for CymaBay Therapeutics in the last year. There are currently 11 hold ratings and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" CBAY shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in CBAY, but not buy additional shares or sell existing shares. View CBAY analyst ratings or view top-rated stocks. What is CymaBay Therapeutics' stock price target for 2024? 12 brokerages have issued twelve-month price objectives for CymaBay Therapeutics' stock. Their CBAY share price targets range from $15.00 to $32.50. On average, they anticipate the company's stock price to reach $28.65 in the next twelve months. This suggests that the stock has a possible downside of 11.8%. View analysts price targets for CBAY or view top-rated stocks among Wall Street analysts. How have CBAY shares performed in 2024? CymaBay Therapeutics' stock was trading at $23.62 at the beginning of the year. Since then, CBAY shares have increased by 37.5% and is now trading at $32.48. View the best growth stocks for 2024 here. When is CymaBay Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024. View our CBAY earnings forecast. How were CymaBay Therapeutics' earnings last quarter? CymaBay Therapeutics, Inc. (NASDAQ:CBAY) released its earnings results on Wednesday, February, 28th. The biopharmaceutical company reported ($0.35) EPS for the quarter, missing analysts' consensus estimates of ($0.31) by $0.04. The biopharmaceutical company earned $0.06 million during the quarter, compared to analysts' expectations of $0.42 million. What ETFs hold CymaBay Therapeutics' stock? ETFs with the largest weight of CymaBay Therapeutics (NASDAQ:CBAY) stock in their portfolio include Invesco Biotechnology & Genome ETF (PBE), SPDR S&P Pharmaceuticals ETF (XPH), AdvisorShares Dorsey Wright Micro-Cap ETF (DWMC), Virtus LifeSci Biotech Clinical Trials ETF (BBC), Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL) and ALPS Medical Breakthroughs ETF (SBIO).iShares Micro-Cap ETF (IWC). What other stocks do shareholders of CymaBay Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other CymaBay Therapeutics investors own include Sorrento Therapeutics (SRNE), NVIDIA (NVDA), Advanced Micro Devices (AMD), OPKO Health (OPK), Pfizer (PFE), Alibaba Group (BABA), Novavax (NVAX), Corbus Pharmaceuticals (CRBP), Energy Transfer (ET) and Viking Therapeutics (VKTX). Who are CymaBay Therapeutics' major shareholders? CymaBay Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Avoro Capital Advisors LLC (9.80%), Vanguard Group Inc. (5.56%), Vanguard Group Inc. (5.50%), Price T Rowe Associates Inc. MD (3.94%), Price T Rowe Associates Inc. MD (3.94%) and Perceptive Advisors LLC (3.55%). Insiders that own company stock include Charles Mcwherter, Daniel Menold, Dennis D Kim, Janet Dorling, Kurt Von Emster, Paul T Quinlan and Sujal Shah. View institutional ownership trends. How do I buy shares of CymaBay Therapeutics? Shares of CBAY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:CBAY) was last updated on 3/28/2024 by MarketBeat.com Staff From Our PartnersTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeGrab Your Free Bitcoin Today!Crypto Swap ProfitsTop Project Outperforms BTC in 2023…Crypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading Academy“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisorySHOCKING Footage From Tesla Gigafactory In Austin, TexasInvestorPlaceFed launches fourth dollar overhaulStansberry Research Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CymaBay Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.